4 Stocks Dragging In The Health Services Industry

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 81 points (0.5%) at 15,076 as of Thursday, June 13, 2013, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,136 issues advancing vs. 827 declining with 99 unchanged.

The Health Services industry currently sits up 0.4% versus the S&P 500, which is up 0.6%. On the negative front, top decliners within the industry include St Jude Medical ( STJ), down 0.58, and DaVita HealthCare Partners ( DVA), down 0.60. Top gainers within the industry include Edwards Life ( EW), up 3.5%, Medtronic ( MDT), up 1.4%, Covidien ( COV), up 1.3%, Smith & Nephew ( SNN), up 1.1% and HCA Holdings ( HCA), up 0.9%.

TheStreet Ratings group would like to highlight 4 stocks pushing the industry lower today:

4. Fresenius Medical Care AG & Co. KGaA ( FMS) is one of the companies pushing the Health Services industry lower today. As of noon trading, Fresenius Medical Care AG & Co. KGaA is down $0.24 (-0.7%) to $34.97 on heavy volume Thus far, 119,748 shares of Fresenius Medical Care AG & Co. KGaA exchanged hands as compared to its average daily volume of 158,800 shares. The stock has ranged in price between $34.90-$35.11 after having opened the day at $34.95 as compared to the previous trading day's close of $35.21.

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, operates in the field of dialysis care and dialysis products for the treatment of end-stage renal disease. Fresenius Medical Care AG & Co. KGaA has a market cap of $21.3 billion and is part of the health care sector. The company has a P/E ratio of 18.2, above the S&P 500 P/E ratio of 17.7. Shares are up 2.7% year to date as of the close of trading on Wednesday. Currently there are 4 analysts that rate Fresenius Medical Care AG & Co. KGaA a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Fresenius Medical Care AG & Co. KGaA as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in stock price during the past year, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Fresenius Medical Care AG & Co. KGaA Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Sirona Dental Systems ( SIRO) is down $1.39 (-2.0%) to $66.67 on heavy volume Thus far, 648,298 shares of Sirona Dental Systems exchanged hands as compared to its average daily volume of 341,800 shares. The stock has ranged in price between $66.20-$67.61 after having opened the day at $67.61 as compared to the previous trading day's close of $68.06.

Sirona Dental Systems, Inc., together with its subsidiaries, develops, manufactures, and markets dental equipment for dentists worldwide. It operates in four segments: Dental CAD/CAM Systems, Imaging Systems, Treatment Centers, and Instruments. Sirona Dental Systems has a market cap of $3.8 billion and is part of the health care sector. The company has a P/E ratio of 28.9, above the S&P 500 P/E ratio of 17.7. Shares are up 7.2% year to date as of the close of trading on Wednesday. Currently there are 10 analysts that rate Sirona Dental Systems a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Sirona Dental Systems as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, good cash flow from operations and growth in earnings per share. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Sirona Dental Systems Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Mindray Medical International ( MR) is down $0.72 (-1.8%) to $40.49 on heavy volume Thus far, 569,390 shares of Mindray Medical International exchanged hands as compared to its average daily volume of 638,100 shares. The stock has ranged in price between $40.35-$41.20 after having opened the day at $41.00 as compared to the previous trading day's close of $41.21.

Mindray Medical International Limited, through its subsidiary, Shenzhen Mindray, develops, manufactures, and markets medical devices worldwide. It operates in three segments: Patient Monitoring and Life Support Products, In-Vitro Diagnostic Products, and Medical Imaging Systems. Mindray Medical International has a market cap of $4.9 billion and is part of the health care sector. The company has a P/E ratio of 24.7, above the S&P 500 P/E ratio of 17.7. Shares are up 26.0% year to date as of the close of trading on Wednesday. Currently there are 4 analysts that rate Mindray Medical International a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Mindray Medical International as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Mindray Medical International Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Cigna ( CI) is down $0.59 (-0.8%) to $68.85 on average volume Thus far, 840,254 shares of Cigna exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $68.07-$69.29 after having opened the day at $69.29 as compared to the previous trading day's close of $69.44.

Cigna Corporation, a health services organization, provides insurance and related products and services in the United States and internationally. Cigna has a market cap of $20.0 billion and is part of the health care sector. The company has a P/E ratio of 15.4, below the S&P 500 P/E ratio of 17.7. Shares are up 29.9% year to date as of the close of trading on Wednesday. Currently there are 9 analysts that rate Cigna a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Cigna as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Cigna Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%